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Abstract 
Background 
Steroid-sensitive nephrotic syndrome is the most common form of nephrotic 
syndrome in childhood, defined by the response to treatment with glucocorticoids 
with consequent remission. Whilst most children eventually experience spontaneous 
resolution of the disease, some have a difficult course with frequent relapses or 
steroid-dependence (FRSDNS). The consequent steroid toxicity often prompts 
administration of other immunosuppressive drugs, traditionally cyclophosphamide. 
Recently, rituximab has been reported as effective in this disorder, but long-term 
experience is lacking. 
 
Methods 
Retrospective note review of all children with FRSDNS treated with a first course of 
cyclophosphamide and/or rituximab in our centre between December 2006 and April 
2015. We reviewed time to first relapse after treatment, co-medications and side 
effects. 
Results 
A total of 102 children were treated with cyclophosphamide (79) and/or rituximab 
(42). Of these, 34 received cyclophosphamide prior to rituximab. Median time to first 
relapse was 7 months after cyclophosphamide and 14 months after rituximab. 
Documented side effects of cyclophoshamide included neutropaenia, hair loss and 
haemorrhagic cystitis (1). Rituximab was associated with an allergic reaction at 
infusion in 2 patients. 
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Conclusion 
Rituximab was used in children with the most difficult to treat FRSDNS, yet was 
associated with longer remission time and less side effects than cyclophosphamide. 
A randomized controlled trial is needed to directly compare these drugs.  
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Introduction 
Idiopathic nephrotic syndrome is a rare disease in childhood with an estimated 
incidence of 16:100000 [1]. Most children have so-called steroid-sensitive nephrotic 
syndrome (SSNS), defined by the response of the disease to treatment with 
glucocorticoids, typically prednisolone. A kidney biopsy, which nowadays is rarely 
obtained, would typically show “minimal changes” on light microscopy and foot 
process effacement on electron microscopy. The aetiology is unclear, but thought to 
be immune-mediated, as “immune stimulators” such as infections and vaccines are 
classical triggers for the disease and because of the response to 
immunosuppressive medications. The spectrum of severity is wide, with some 
patients only suffering a single episode, whilst others have a chronic relapsing 
course with consequent toxicity from repeated or ongoing use of glucocorticoids, 
including obesity, striae distensae, stunted growth, behavioural abnormalities and 
osteoporosis. Fortunately, the disease resolves spontaneously in the majority of 
children, with less than 10% of patients having ongoing relapses into adulthood, 
although this proportion may be higher in FRSDNS [2]. Consequently, the main aim 
of the treating physician is to guide the individual patient safely through the active 
disease period with the least side effects. To minimise steroid toxicity, other 
immnosuppressive drugs are frequently used, also called “steroid-sparing 
medications”. These include cyclophosphamide, mycophenolate mofetil and 
calcineurin inhibitors [1]. 
Over the last years, case reports have emerged on the successful use of rituximab in 
FRSDNS, as well as some case series [3-6]. These reports demonstrate that 
rituximab is increasingly used in FRSDNS and a few recent randomised controlled 
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trials suggest a benefit of rituximab in minimising the use of steroids and other 
immunosuppressive drugs [8-11].  
The nephrotic clinic at Great Ormond Street Hospital for Children (GOSH) is a 
referral clinic for children with difficult to treat nephrotic syndrome. Patients with 
SSNS are usually cared for by paediatricians in their local hospital, but get referred 
to GOSH, if they develop FRSDNS. The decision for and choice of steroid–sparing 
medications is made in conjunction with the family after discussion of the benefits 
and side effects of the individual drugs. In those with persistent relapses and/or 
unacceptable side effects despite one or more steroid-sparing drugs, we have 
increasingly used rituximab to achieve prolonged remission. However, long-term 
experience with the use of this drug in FRSDNS is still scarce and we thus reviewed 
data from our own centre to better inform treatment choice in children with FRSDNS. 
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Methods 
We performed a retrospective review of notes from patients with SSNS, who 
received treatment with a first course of cyclophosphamide and/or rituximab. 
Patients were identified from a database maintained by the nephrotic service. We 
first used rituximab in FRSDNS in December 2006 and thus chose the time period 
for this review from this date to April 2014, to ensure a minimum of 1 year of follow-
up. For comparison, we reviewed the notes of those patients who received a first 
course of cyclophosphamide during the same time period. We only included those 
patients, who received at least 50% of the prescribed dose of either rituximab or 
cyclophosphamide to ensure sufficient drug was given to expect a response. 
We analysed time to first relapse after treatment with either of these drugs, as well 
as documented side effects and other immunosuppressive medications used. 
In our clinical practice, a relapse is defined as 3 days of 3+ on dipstick for protein, 
plus presence of oedema and/or hypoalbuminaemia (<25g/l). 
Time to relapse was compared and graphically illustrated using SPSS version 22.0 
software. Mann-Whitney U test was used to assess significance in the comparison of 
median values. 
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Results 
Patient cohort 
A total of 104 children (70 male, 34 female) were identified who had been prescribed 
a first course of cyclophosphamide or rituximab during the stated period: 79 patients 
(53 male) had been prescribed cyclophosphamide (standard dose of either 2 mg/kg 
for 3 months or 3 mg/kg for 2 months) with a median age of 6 years (range 1-15 
years) at the beginning of the course. All patients prescribed cyclophosphamide 
received at least 50% of the dose. 
Forty-four patients (34 male) had been prescribed rituximab, either a single dose of 
750mg/m2 (N=10), or 2 doses of 750 mg/m2 approximately 2 weeks apart (N=34). 
The infusion of rituximab had to be abandoned at the very beginning in 2 patients 
due to an allergic reaction. These 2 patients were not included in the analysis, as 
they did not receive sufficient dose to expect an effect. 
Of the 42 patients who received rituximab, 35 (83%) had received a course of 
cyclophosphamide previously, including 20 who received it within the review period. 
Baseline data for the patients are presented in table 1. 
 
Time to first relapse 
Median time to relapse was 7 months following cyclophosphamide treatment and 14 
months following rituximab (see Figure 1).  
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Long-term remission (>24 months) was assessed in patients, who had at least 2 
years of follow-up after treatment and was achieved in 24% after cyclophosphamide 
and 32% after rituximab.  
 
Other immunosuppressive medications at commencement of cyclophosphamide or 
rituximab treatment  
At the time of commencement of cyclophosphamide, all children received 
prednisolone, at a median dose of 0.4mg/kg/day. 
37 patients receiving a first course of cyclophosphamide received levamisole prior to 
starting, which was stopped in all when starting cyclophosphamide. Two patients 
received treatment with a CNI, which was also stopped at commencement of 
cyclophosphamide. For the remaining 40 children cyclophosphamide was the first 
“steroid sparing” medication prescribed. 
Of the 42 children receiving rituximab, 14 were treated with maintenance 
prednisolone only, 18 were treated with a calcineurin inhibitor (CNI) and 
prednisolone, 8 with mycophenolate mofetil (MMF) and prednisolone, and 2 with a 
combination of CNI + MMF + prednisolone.  In total, 28 children (67%) received at 
least 2 other immunosuppressants including prednisolone at the time of rituximab 
administration. Median dose of Prednisolone at the time of the rituximab treatment 
was 0.3 mg/kg/d.  
 
Immunosuppressive medications at first relapse after cyclophosphamide or rituximab 
treatment 
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Within the cyclophosphamide group 67 children (84%) were weaned off prednisolone 
with a median time to stop prednisolone of 3 months. Median time off prednisolone 
until 1st relapse was 3 months. 12 patients (16%) were still on maintenance 
prednisolone when they relapsed. 
Within the rituximab group, 36 children (86%) were weaned off prednisolone with a 
median time to stop prednisolone of also 3 months. Six patients (14%) relapsed 
whilst still on prednisolone. Median time off prednisolone until 1st relapse was 12 
months. In 29 children (69%) all immunosuppressive medications were weaned off 
within a median time of 4 months. Seven children weaned off prednisolone, but 
relapsed whilst still receiving a CNI or MMF. 
 
Side effects 
Side effects were not systematically documented in the notes, especially minor ones, 
such as hair loss and thus are difficult to compare. However, in 3 patients receiving 
cyclophosphamide there was documented neutropenia with consequent adjustment 
of the dose and/or premature stopping of the drug. One patient had to be 
hospitalised due to bladder obstruction from a clot from haemorrhagic cystitis and 
required surgical bladder washout by cystoscopy under general anaesthesia. 
In the patients receiving a first course of rituximab, no specific side effects were 
noted, except for the allergic reaction in 2, which prevented further administration of 
the drug. 
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Patients who had received cyclophosphamide and rituximab 
Of the 42 patients who received rituximab, 34 had previously also received 
cyclophosphamide, 19 within the review period. Time between the 2 treatments 
varied between 8 to 173 months. To assess the drug effect within the same cohort of 
children, we compared time to relapse for the 2 drugs in these 34 patients. 
The median time to relapse after receiving cyclophosphamide was 2 months (range 
0 to 29 months). The median time to relapse after receiving rituximab was 15 months 
(1-73 months, with 12 patients so far not having had a relapse). 
We also assessed the median time to relapse after rituximab in those children who 
had previously received cyclophosphamide to those who did not. Median time to 
relapse in children with a previous cyclophosphamide course (N=34) was 16 months 
compared to 9 months in those without (N=8). This difference was not significantly 
different (P=0.305). 
 
Rituximab dosing 
Initially, all children treated with rituximab received 2 doses of 750 mg/m2, as 
adapted from our protocol for Systemic Lupus Erythematodes [12]. With reports 
emerging of single-dose treatment in FRSDNS, we changed the protocol to a single 
dose of 750 mg/m2. A total of 8 patients were treated with this single dose regime, 
but when 6 of these relapsed within 8 months, we reverted to the old two-dose 
protocol. The median time to relapse in the two-dose regimen (N=34) was 16 months 
(range 1-73), whereas it was 5 months (range 1-36) with a single dose, which was 
significantly different (p=0.03). 
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Discussion 
This is a retrospective review of the response to cyclophosphamide and/or rituximab 
in children with FRSDNS. Thus, a direct comparison between the 2 drugs is possible 
only to a limited extent, as clinical circumstances were not controlled, especially with 
respect to medications received previously and during the course. Nevertheless, our 
data suggest that rituximab plays an important role in the treatment of FRSDNS with 
a median time to relapse of 14 months compared to 7 months after 
cyclophosphamide (Figure 1). The response to rituximab in our centre with regards 
to time to relapse is similar to that in other recent reports in children with FRSDNS of 
6 -18 months [6, 9-11, 13]. The response to cyclophosphamide recorded here is also 
well within the range of reports in the literature [14] and is comparable to the efficacy 
of levamisole and MMF with a recently reported median relapse free interval of 
approximately 7-8 months [15]. 
A key aim of these so-called steroid-sparing agents is to minimise the use of 
glucocorticoids. Whilst the vast majority of children (84% after cyclophosphamide 
and 86% after rituximab) could come off prednisolone completely, this effect was 
much more sustained after rituximab, consistent with the prolonged remission: the 
median time off prednisolone after rituximab was 12 months, compared to only 3 
months after cyclophosphamide. 
Some of this apparent superior effect may have been simply due to the more 
intensive immunosuppression received concomitantly: at the start of the respective 
treatment courses, children receiving cyclophosphamide were only receiving 
prednisolone as additional immunosuppression, whereas the majority of patients 
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(67%) receiving rituximab received at least one additional immunosuppressant 
besides prednisolone, that is a CNI and/or MMF. However, this is not supported by 
the assessment of the number of immunosuppressants at the time of first relapse, as 
the majority (69%) of children could come off all immunosuppressants after 
rituximab. Indeed, rather than providing an alternative explanation for the prolonged 
remission after rituximab, the higher number of immunosuppressants at the 
beginning of treatment more likely reflects the severity of the disease: in our clinical 
practice at GOSH, treatment with rituximab has so far been reserved for patients 
with the most difficult to treat FRSDNS, who either continue to have relapses despite 
the use of one or more steroid sparing agents or experience side effects deemed 
unacceptable. In contrast, cyclophosphamide is typically the first steroid-sparing 
immunosuppressive drug used in children with FRSDNS referred to our clinic. Thus, 
rituximab was given only to a selected cohort with the most difficult to treat form of 
FRSDNS. We aimed to account for this potential selection bias by comparing the 
effect of the 2 drugs in those patients who had received both drugs. When analysing 
just those 34 patients, the superior response to rituximab is even more remarkable 
with a median time to relapse of 17 months compared to only 2.5 months after 
cyclophosphamide. It is, of course, also possible, that some patients with FRSDNS 
respond better to cyclophosphamide than to rituximab. The patients, who entered 
long-term remission after cyclophosphamide and never received rituximab could be 
examples for such superior cyclophosphamide responders. The superior effect of 
cyclophosphamide in these patients would not be captured in our study, as rituximab 
was given only to those patients who continued to have relapses with other 
treatments. Thus, the nature of this retrospective review may bias against 
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cyclophosphamide. Only a prospective study would be able to answer this question 
in an unbiased fashion. 
The apparent superior efficacy of rituximab in FRSDNS appears not to be 
complicated by more severe side effects. Whilst not systematically documented, the 
only noted side effects were an allergic reaction to the drug during infusion. 
Nevertheless, severe complications have been reported after rituximab, most notably 
progressive multifocal encephalopathy from reactivated Jacob-Creutzfeld virus and 
progressive pulmonary fibrosis [16-18]. Fortunately, these severe complications 
appear to be exceedingly rare and since these patients received other concomitant 
immunosuppressive treatment, the precise contributing effect of rituximab is difficult 
to assess. Interestingly, in a trial of rituximab in lupus nephritis, the frequency of 
reported side effects was higher in the placebo than in the rituximab group [19]. 
Currently, no consensus exists about the optimal dosage of rituximab in FRSDNS 
with reported dosages ranging from 375 to 1500 mg/m2 divided into 1 to 4 injections 
[3]. In the original indication of lymphoma treatment, the dose of 1500 mg/m2 divided 
into 4 injections was developed and this dose has been adapted for subsequent 
indications, such as SLE [16]. However, in a few recent trials in FRSDNS, only a 
single injection of 375 mg/m2 has been used with apparent good effect [9, 11]. 
Whilst repeated dosing results in extended half-life [20], it is unclear whether this 
translates into clinical benefit.  Evidence from some case series seems to suggest 
that repeated dosing may be associated with longer remission compared to single-
dose treatment [21], which fits our experience here. Further studies are needed to 
identify the optimal dosage for this indication in children, but if equivalent a smaller 
drug dose or decreased frequency would obviously be preferable with respect to cost 
and potential side effects. 
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Conclusions  
This retrospective review clearly supports the efficacy of rituximab in FRSDNS, 
which is superior to cyclophosphamide: time to first relapse and time off steroid post 
treatment was 2 and 4 times longer, respectively, after rituximab. Superiority was 
even more pronounced when just reviewing the most difficult to treat patients, that is 
those, who received both cyclophosphamide and rituximab during the course of their 
disease. 
Our data raise the question, whether rituximab should continue to be reserved only 
for the most difficult to treat patients or whether it could be a superior first line 
steroid-sparing agent in patients with FRSDNS. Randomized, controlled clinical trials 
are needed to properly address this question. 
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Table 1 
 CycP only Ritux only CycP and Ritux 
N 59 8 34 
Male (%) 66 87 82 
Median age at 
treatment (years) 
6 7.5 11  
Biopsy , N (%) 11 (19) 6 (75) 15 (44) 
MCN, N (%) 9 (82) 5 (83) 11 (73) 
FSGS, N (%) 2 (18) 1 (17) 4 (27) 
Previous steroid 
sparing meds, N (%) 
29 (49) 8 (100) 30 (88) 
 
Levamisole, N (%) 28 (47) 2 (25) 18 (53) 
CNI, N (%) 1 (2) 8 (100) 25 (74) 
MMF, N (%) 1 (2) 5 (63) 9 (26) 
Table 1: Baseline data of patients  
Numbers for previous steroid sparing medications do not necessarily add up, as some patients 
received more than one such medication prior to cyclophosphamide (CyCP) or Rituximab (Ritux). 
Median age at treatment in the group receiving both CyCP and Ritux refers to age at Ritux 
treatment. Similarly, for the same group, previous steroid sparing medications refer to medications 
prior to Ritux treatment. CNI: Calcineurin inhibitor, MMF: Mycophenolate Mofetil 
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Figure 1 
Kaplan-Meyer graph of time to first relapse in children having received a first course of rituximab 
(blue line, N=42) or cyclophosphamide (red line, N=79). Median time to first relapse was 14 months 
after rituximab and 7 months after cyclophosphamide. 
 
 
